Vas Narasimhan Archives - CDR – Chain Drug Review

Novartis announces change in Sandoz leadership

March 15, 2019 by Chain Drug Review Francesco Balestrieri, Novartis, Richard Francis, Sandoz, Vas Narasimhan Leading Headlines, Supplier News

BASEL – Novartis announced this week that Richard Francis will be stepping down as chief executive officer of Sandoz, a Novartis division, and as a member of the executive committee of Novartis on March 31. Francesco Balestrieri, currently region head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.

GSK to buy out Novartis in consumer health joint venture

March 27, 2018 by Chain Drug Review consumer health care, Emma Walmsley, GlaxoSmithKline, GSK-Novartis Consumer Healthcare, Novartis, Pfizer Consumer Healthcare, Vas Narasimhan Business, Leading Headlines, Pharmacy, Supplier News

LONDON and BASEL, Switzerland — GlaxoSmithKline plc plans to buy Novartis’ 36.5% stake in their consumer health care joint venture for $13 billion. Under the agreement announced Tuesday, Novartis’ shares in the joint venture will be canceled, and the joint venture will pay the buyout price to Novartis. GSK has entered into a committed facilities agreement to